Clinical Evidence ClosureFast™ RFA System

Building long-term evidence with high clinical standards

Alert Indications, Safety, and Warnings

Go Gap-free For Patented Performance

The ClosureFast procedure, with its patented overlap design, is the only RFA procedure with published long-term clinical data demonstrating safety and efficacy, with a 91.9% closure rate at 5 years.1,2

  • 250+ published clinical studies and articles3
  • Over 2 million patients have been treated with the ClosureFast procedure in over 100 countries around the world.4

Legs before and six weeks after ClosureFast procedure

Individual results may vary. Images courtesy of Jonathan Calure, M.D., of Maryland Vein Professionals.

5-year Study Results

91.9% closure rate at 5 years1

94.9% reflux-free rate at 5 years1

72% improvement in VCSS scores at 5 years5

Additional Resources

Connect With Us

Connect with a Medtronic representative and receive updates and ongoing information.

Connect Now
ClosureFast radiofrequency ablation system on gradient background

ClosureFast Radiofrequency Ablation System

Learn More

References

1

Proebstle TM, Alm BJ, Göckeritz O, et al. Five-year results from the prospective European multicentre cohort study on radiofrequency segmental thermal ablation for incompetent great saphenous veins. Br J Surg. February 2015;102(3):212-218.

2

ClosureFast and ClosureFast RFS Patents. Medtronic data on file, 2022.

3

Medtronic ClosureFast Procedure Publications. Medtronic data on file, 2019.

4

ClosureFast Procedures. Medtronic data on file, 2019.

5

Morrison N, Gibson K, Vasquez M, et al. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. November 2020;8(6):978-989.